<DOC>
	<DOCNO>NCT00966914</DOCNO>
	<brief_summary>Tavocept investigational drug develop see increase survival patient treat chemotherapy well see prevent reduce side effect chemotherapy . This research study aim try find people advance adenocarcinoma lung treat standard combination chemotherapy drug live long also treat investigational drug call `` Tavocept . '' Another objective research study find whether Tavocept help prevent reduce side-effects like kidney damage , anemia , nausea vomit occur drug combination . The drug combination use research study include either paclitaxel cisplatin , docetaxel cisplatin . These drug combination approve used treat people advance NSCLC . Every patient research study treat standard chemotherapy primary NSCLC form either docetaxel paclitaxel ( recommend research study doctor ) , give combination cisplatin .</brief_summary>
	<brief_title>Phase 3 Study Tavocept Versus Placebo Patients With Newly Diagnosed Relapsed Advanced Primary Adenocarcinoma Lung Treated With Docetaxel Paclitaxel Plus Cisplatin</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Confirmed histopathological diagnosis inoperable advanced primary adenocarcinoma ( include bronchioalveolar cell carcinoma ) lung No prior systemic treatment nonsmall cell lung cancer include chemotherapy , immunotherapy , hormonal therapy , target therapy investigational drug Small cell , squamous cell , large cell undifferentiated form mixed ( eg , small cell adenocarcinoma squamous adenocarcinoma ) histopathological cytological diagnosis primary lung cancer Adenocarcinoma arise primary site lung Patients without documented Stage 4 disease ( accordance AJCC TMM Staging System 7th edition ) Patients unstable CNS mets within 21 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>